Immunological and endocrinological response to growth hormone therapy in short children

M. Bozzola, R. Maccario, M. Cisternino, M. De Amici, A. Valtorta, A. Moretta, I. Biscaldi, R. M. Schimpff

Research output: Contribution to journalArticle

Abstract

We investigated the influence of human growth hormone (hGH) on mitogen-stimulated lymphoproliferation, in vitro IgM production, serum levels of immunoglobulins, somatomedin-C (Sm-C) values and serum growth-promoting activity (Thymidine Activity, TA) in 18 short children, aged between 6.6-14.5 years, undergoing a 3-month course of hGH therapy. Blood was collected the day before treatment (Group A), on the 5th day after patients were administered hGH daily (0.1 U/kg) i.m. for 4 days (Group B), after a 3-month course of hGH injected three times weekly, and finally before (Group C) and 24 h after an extra injection (Group D). In vitro IgM production from the patients' unstimulated lymphocytes decreased from 277 ± 41 (Group A) to 168 ± 38 (Group B), to 119 ± 43 (Group C) and then to 119 ± 28 ng/ml (Group D) (p <0.05). Using PWM-stimulated lymphocytes in vitro IgM production decreased from 2,015 ± 464 (Group A) to 1,116 ± 316 (Group B), then to 511 ± 170 (Group C) and 968 ± 295 ng/ml (Group D) (p <0.02). The variation of this decrease could be correlated with the variation of growth velocity during treatment (r = 0.619, p <0.05). In contrast, no significant changes were found following therapy either in serum levels of IgA, IgE, IgG, IgM, Sm-C and TA, or in phytohemagglutinin, concanavalin A and pokeweed mitogen-stimulated lymphoproliferation. Our data suggest that there is some relationship between growth hormone, growth and immunity.

Original languageEnglish
Pages (from-to)675-680
Number of pages6
JournalActa Paediatrica Scandinavica
Volume77
Issue number5
Publication statusPublished - 1988

Fingerprint

Human Growth Hormone
Growth Hormone
Immunoglobulin M
Insulin-Like Growth Factor I
Thymidine
Serum
Lymphocytes
Pokeweed Mitogens
Phytohemagglutinins
Therapeutics
Growth
Concanavalin A
Mitogens
Immunoglobulin A
Immunoglobulin E
Immunoglobulins
Immunity
Immunoglobulin G
Injections
In Vitro Techniques

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Immunological and endocrinological response to growth hormone therapy in short children. / Bozzola, M.; Maccario, R.; Cisternino, M.; De Amici, M.; Valtorta, A.; Moretta, A.; Biscaldi, I.; Schimpff, R. M.

In: Acta Paediatrica Scandinavica, Vol. 77, No. 5, 1988, p. 675-680.

Research output: Contribution to journalArticle

Bozzola, M, Maccario, R, Cisternino, M, De Amici, M, Valtorta, A, Moretta, A, Biscaldi, I & Schimpff, RM 1988, 'Immunological and endocrinological response to growth hormone therapy in short children', Acta Paediatrica Scandinavica, vol. 77, no. 5, pp. 675-680.
Bozzola, M. ; Maccario, R. ; Cisternino, M. ; De Amici, M. ; Valtorta, A. ; Moretta, A. ; Biscaldi, I. ; Schimpff, R. M. / Immunological and endocrinological response to growth hormone therapy in short children. In: Acta Paediatrica Scandinavica. 1988 ; Vol. 77, No. 5. pp. 675-680.
@article{9fe0bf867e0d48d5be8560686002eeb1,
title = "Immunological and endocrinological response to growth hormone therapy in short children",
abstract = "We investigated the influence of human growth hormone (hGH) on mitogen-stimulated lymphoproliferation, in vitro IgM production, serum levels of immunoglobulins, somatomedin-C (Sm-C) values and serum growth-promoting activity (Thymidine Activity, TA) in 18 short children, aged between 6.6-14.5 years, undergoing a 3-month course of hGH therapy. Blood was collected the day before treatment (Group A), on the 5th day after patients were administered hGH daily (0.1 U/kg) i.m. for 4 days (Group B), after a 3-month course of hGH injected three times weekly, and finally before (Group C) and 24 h after an extra injection (Group D). In vitro IgM production from the patients' unstimulated lymphocytes decreased from 277 ± 41 (Group A) to 168 ± 38 (Group B), to 119 ± 43 (Group C) and then to 119 ± 28 ng/ml (Group D) (p <0.05). Using PWM-stimulated lymphocytes in vitro IgM production decreased from 2,015 ± 464 (Group A) to 1,116 ± 316 (Group B), then to 511 ± 170 (Group C) and 968 ± 295 ng/ml (Group D) (p <0.02). The variation of this decrease could be correlated with the variation of growth velocity during treatment (r = 0.619, p <0.05). In contrast, no significant changes were found following therapy either in serum levels of IgA, IgE, IgG, IgM, Sm-C and TA, or in phytohemagglutinin, concanavalin A and pokeweed mitogen-stimulated lymphoproliferation. Our data suggest that there is some relationship between growth hormone, growth and immunity.",
author = "M. Bozzola and R. Maccario and M. Cisternino and {De Amici}, M. and A. Valtorta and A. Moretta and I. Biscaldi and Schimpff, {R. M.}",
year = "1988",
language = "English",
volume = "77",
pages = "675--680",
journal = "Acta Paediatrica Scandinavica",
issn = "0001-656X",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Immunological and endocrinological response to growth hormone therapy in short children

AU - Bozzola, M.

AU - Maccario, R.

AU - Cisternino, M.

AU - De Amici, M.

AU - Valtorta, A.

AU - Moretta, A.

AU - Biscaldi, I.

AU - Schimpff, R. M.

PY - 1988

Y1 - 1988

N2 - We investigated the influence of human growth hormone (hGH) on mitogen-stimulated lymphoproliferation, in vitro IgM production, serum levels of immunoglobulins, somatomedin-C (Sm-C) values and serum growth-promoting activity (Thymidine Activity, TA) in 18 short children, aged between 6.6-14.5 years, undergoing a 3-month course of hGH therapy. Blood was collected the day before treatment (Group A), on the 5th day after patients were administered hGH daily (0.1 U/kg) i.m. for 4 days (Group B), after a 3-month course of hGH injected three times weekly, and finally before (Group C) and 24 h after an extra injection (Group D). In vitro IgM production from the patients' unstimulated lymphocytes decreased from 277 ± 41 (Group A) to 168 ± 38 (Group B), to 119 ± 43 (Group C) and then to 119 ± 28 ng/ml (Group D) (p <0.05). Using PWM-stimulated lymphocytes in vitro IgM production decreased from 2,015 ± 464 (Group A) to 1,116 ± 316 (Group B), then to 511 ± 170 (Group C) and 968 ± 295 ng/ml (Group D) (p <0.02). The variation of this decrease could be correlated with the variation of growth velocity during treatment (r = 0.619, p <0.05). In contrast, no significant changes were found following therapy either in serum levels of IgA, IgE, IgG, IgM, Sm-C and TA, or in phytohemagglutinin, concanavalin A and pokeweed mitogen-stimulated lymphoproliferation. Our data suggest that there is some relationship between growth hormone, growth and immunity.

AB - We investigated the influence of human growth hormone (hGH) on mitogen-stimulated lymphoproliferation, in vitro IgM production, serum levels of immunoglobulins, somatomedin-C (Sm-C) values and serum growth-promoting activity (Thymidine Activity, TA) in 18 short children, aged between 6.6-14.5 years, undergoing a 3-month course of hGH therapy. Blood was collected the day before treatment (Group A), on the 5th day after patients were administered hGH daily (0.1 U/kg) i.m. for 4 days (Group B), after a 3-month course of hGH injected three times weekly, and finally before (Group C) and 24 h after an extra injection (Group D). In vitro IgM production from the patients' unstimulated lymphocytes decreased from 277 ± 41 (Group A) to 168 ± 38 (Group B), to 119 ± 43 (Group C) and then to 119 ± 28 ng/ml (Group D) (p <0.05). Using PWM-stimulated lymphocytes in vitro IgM production decreased from 2,015 ± 464 (Group A) to 1,116 ± 316 (Group B), then to 511 ± 170 (Group C) and 968 ± 295 ng/ml (Group D) (p <0.02). The variation of this decrease could be correlated with the variation of growth velocity during treatment (r = 0.619, p <0.05). In contrast, no significant changes were found following therapy either in serum levels of IgA, IgE, IgG, IgM, Sm-C and TA, or in phytohemagglutinin, concanavalin A and pokeweed mitogen-stimulated lymphoproliferation. Our data suggest that there is some relationship between growth hormone, growth and immunity.

UR - http://www.scopus.com/inward/record.url?scp=0023729623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023729623&partnerID=8YFLogxK

M3 - Article

C2 - 3201973

AN - SCOPUS:0023729623

VL - 77

SP - 675

EP - 680

JO - Acta Paediatrica Scandinavica

JF - Acta Paediatrica Scandinavica

SN - 0001-656X

IS - 5

ER -